Source
AJMC
Acoramidis (Attruby; BridgeBio Pharma), an oral transthyretin (TTR) stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly slowed the decline in heart failure (HF)–related health status compared with placebo, according to a secondary analysis of the phase 3 ATTRibute-CM (NCT03860935) randomized clinical trial published online in JAMA Cardiology.
“In this secondary analysis of the ATTRibute-CM randomized clinical trial among patients with ATTR-CM, acoramidis attenuated the decline in patient-reported health status vs placebo, with sustained results that were consistent across prespecified subgroups,” wrote the researchers of the study.
News Url